Sana Biotechnology(SANA) - 2024 Q4 - Annual Results

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cel ...